two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin ( 40 mg/m2 ) , or epirubicin ( 40 mg/m2 ) or mitoxantrone ( 12 mg/m2 ) each combined with cyclophosphamide ( 600 mg/m2 ) i.v .
C0013089
doxorubicin
C0014582
epirubicin